Director at Zura Bio (ZURA) awarded 37,812 options with year-long vesting

Rhea-AI Filing Summary

Zura Bio Ltd director Mark Eisner received a grant of options to acquire 37,812 shares, described as a "Share Option (Right to Buy)" at an exercise price of $0.0000 per share. These options were awarded as a grant or other acquisition.

The option vests in twelve substantially equal monthly installments over a one-year period starting on February 21, 2026. Any remaining unvested portion will vest on the day immediately preceding the next annual meeting of shareholders following the grant date, as long as he continues in service through each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eisner Mark

(Last) (First) (Middle)

C/O ZURA BIO LIMITED

1489 W. WARM SPRINGS RD. #110

(Street)

HENDERSON NV 89014

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zura Bio Ltd [ ZURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$6.53	02/21/2026		A		37,812		(1)	02/21/2036	Class A Ordinary Shares	37,812	$0	37,812	D

Explanation of Responses:

1. This option vests in twelve substantially equal monthly installments over a one-year period measured from February 21, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.

	/s/ Kim Davis, Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Zura Bio (ZURA) report for Mark Eisner?

Zura Bio reported that director Mark Eisner received a grant of options for 37,812 shares. The award is classified as a grant or other acquisition with an exercise price of $0.0000 per share, expanding his potential equity stake in the company over time.

How many Zura Bio (ZURA) options were granted to director Mark Eisner?

Mark Eisner was granted options covering 37,812 Zura Bio shares. The filing shows this entire amount as held directly after the transaction, reflecting a single grant-based acquisition rather than multiple trades or open-market purchases.

What are the vesting terms of Mark Eisner’s Zura Bio (ZURA) option grant?

The option vests in twelve substantially equal monthly installments over one year from February 21, 2026. Any remaining unvested portion vests immediately before the next annual shareholder meeting, contingent on his continued service through each vesting date.

Is Mark Eisner’s Zura Bio (ZURA) option grant subject to continued service?

Yes, vesting of Mark Eisner’s options depends on continued service. Monthly vesting and the final vesting immediately before the next annual shareholder meeting both require that he remain in service with Zura Bio on each applicable vesting date.

What type of security did Mark Eisner receive from Zura Bio (ZURA)?

Mark Eisner received a "Share Option (Right to Buy)" security. This derivative award gives him the right to acquire 37,812 Zura Bio shares at an exercise price of $0.0000 per share, subject to the multi-step vesting schedule described in the filing.